We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-12.6%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$508M
AUM Growth
-$109M
Cap. Flow
+$26.4M
Cap. Flow %
5.19%
Top 10 Hldgs %
74.09%
Holding
34
New
7
Increased
6
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$25.1M
2
COGT icon
Cogent Biosciences
COGT
+$20.1M
3
GHRS icon
GH Research
GHRS
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$11.8M
5
AKUS
Akouos Inc
AKUS
+$9.43M

Top Sells

Rank Stock Value
1
LONA
LeonaBio Inc
LONA
+$13.5M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.5M
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$12.2M
4
NUVL
Nuvalent
NUVL
+$11.2M
5
LENZ
LENZ Therapeutics
LENZ
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
1
DELISTED
Tricida, Inc. Common Stock
TCDA
$69M 13.6%
7,132,079
+2,637,228
+59% +$25.1M
ACRS icon
2
Aclaris Therapeutics
ACRS
$726M
$63.7M 12.55%
4,563,962
– –
RLMD icon
3
Relmada Therapeutics
RLMD
$557M
$43.1M 8.49%
2,270,072
– –
TVTX icon
4
Travere Therapeutics
TVTX
$5.2B
$41.5M 8.17%
1,711,102
-283,895
-14% -$7.14M
COGT icon
5
Cogent Biosciences
COGT
$6.65B
$36.4M 7.17%
4,038,117
+2,949,300
+271% +$20.1M
GHRS icon
6
GH Research
GHRS
$1.93B
$31.8M 6.26%
3,185,573
+1,134,513
+55% +$14.7M
TIL icon
7
Instil Bio
TIL
$48.3M
$27.7M 5.46%
299,883
-43,371
-13% -$6.14M
CLDX icon
8
Celldex Therapeutics
CLDX
$2.99B
$23.3M 4.59%
865,116
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.09B
$21.4M 4.22%
1,852,919
– –
VTGN icon
10
VistaGen Therapeutics
VTGN
$9.89M
$18.2M 3.59%
689,910
+155,000
+29% +$5.47M
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.3M 3.01%
3,156,803
– –
WHWK
12
Whitehawk Therapeutics
WHWK
$190M
$14.5M 2.85%
1,173,518
-355,884
-23% -$5.29M
INZY
13
DELISTED
Inozyme Pharma
INZY
$12.9M 2.55%
+2,709,987
New +$11.8M
AKUS
14
DELISTED
Akouos Inc
AKUS
$12.5M 2.46%
+2,667,119
New +$9.43M
LIAN
15
DELISTED
LianBio American Depositary Shares
LIAN
$11.6M 2.29%
5,378,341
– –
JBIO
16
Jade Biosciences
JBIO
$1.2B
$9.23M 1.82%
16,869
+12,554
+291% +$6M
TRVI icon
17
Trevi Therapeutics
TRVI
$2.59B
$8.57M 1.69%
+3,050,022
New +$7.49M
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.56M 1.69%
489,618
-794,203
-62% -$12.5M
ANNX icon
19
Annexon
ANNX
$834M
$7.27M 1.43%
+1,928,477
New +$5.89M
SVRA icon
20
Savara
SVRA
$1.12B
$6.26M 1.23%
4,117,530
+2,212,265
+116% +$2.91M
LYRA
21
DELISTED
LYRA THERAPEUTICS INC
LYRA
$5.22M 1.03%
+18,483
New +$5.03M
PRVB
22
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$4.47M 0.88%
1,118,653
– –
ALT icon
23
Altimmune
ALT
$552M
$4.32M 0.85%
369,306
-390,413
-51% -$2.41M
ATYR
24
aTyr Pharma
ATYR
$47.6M
$3.96M 0.78%
1,398,889
– –
AFMD
25
DELISTED
Affimed
AFMD
$3.96M 0.78%
142,857
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2022 Portfolio in Review

As of Q2 2022, VR Adviser held 34 positions worth $508M, down 18% from $617M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser deployed $26.4M of net new capital in Q2 2022, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was Inozyme Pharma: 2,709,987 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Chinook Therapeutics, Inc. Common Stock, an estimated $12.5M trimmed.

  • VR Adviser's largest Q2 2022 buy was Inozyme Pharma: 2,709,987 shares worth $12.9M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q2 2022, an estimated $25.1M increase.
  • VR Adviser's biggest Q2 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $12.5M.
  • VR Adviser fully exited LeonaBio Inc in Q2 2022, selling an estimated $13.5M.
  • VR Adviser's ten largest holdings make up 74% of its $508M portfolio in Q2 2022.
  • VR Adviser opened 7 new positions and closed 7 in Q2 2022.
  • VR Adviser's portfolio value fell 18% quarter-over-quarter to $508M.

Based on VR Adviser's 13F filing for Q2 2022, filed 15 Aug 2022.